Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI318 in Advanced Cutaneous Squamous Cell Carcinoma
NCT04611321Phase 2Terminated
- Sponsor
- Innovent Biologics
- Start
- Dec 2020
- Primary completion
- Mar 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of reozalimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Innovent Biologics. Primary endpoint: Overall Response Rate at 24 months. Started Dec 2020; status: terminated.
02
Drugs
reozalimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04611321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04611321.